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Hepatic fibrosis is the end result scarring of extensive
damage to the parenchymal structure with collagen
fibers proliferation. The key event is the local
inflammation induced by a myriad causes but most
commonly by the damage induced by chronic viral
hepatitis though hepatic steatosis and concomitant HIV
infection is being increasingly recognized both as a
cause and companion finding.1,2 On the one hand,
inflammatory reaction triggers the hepatic stellate cells
to deposit fibrous material at the site of injury. On the
other hand, intracellular oxidative stress causes
mitochondrial and endoplasmic reticulum dysfunction
with resultant production of the biochemical mediators of
injury.3 Alpha 2(1) collagen expression in cultured liver
cells has been shown to act as a profibrogenic cytokine
by altering collagen gene expression.4 Regardless of
the cause, the end result of fibrosis is increased liver
stiffness and scarring with continued structural changes
leading to cirrhosis and even hepatocellular carcinoma.
Evaluation of fibrosis, therefore, remains an important
issue in the management of any chronic liver disease
particularly with reference to hepatitis and hepatic
steatosis.
There are many direct and indirect methods for this
evaluation ranging from biopsy - the gold standard - to
radiological imaging modalities to indirect biochemical
indices. Biopsy is an invasive method associated with
definite complications and sampling error is argued as a
limitation.5 Non-invasive diagnosis is ideally desired.
Many combinations and models have been developed to
achieve this aim. The most popular has been AST - to -
platelet - ratio index (APRI) with  specificity ranging  from
67-97% and NPV of about  80% which mainly serves to
exclude marked fibrosis.6 Another combined index is
FIB4 which combines platelet count, AST and ALT
levels with age, and a value of 1.45 or greater predicts
significant fibrosis.7 Other routine indices such as Forn's
index (using age, gamma glutamyl transpeptidase, total
serum cholesterol and platelets) and non-routine
measurements of extracellular matrix remodelling
markers, Hyaluronic acid and Methacetin breath tests
and even mathematical models have been utilized in the
non-invasive evaluation of fibrosis and  shown to be
expensive and not markedly superior over each other.8,9
Fibroscore is another development in this regard as
reported by Ashraf et al. in the current issue.
The available local literature is increasingly brimming
with initially biopsy-based and now clinico-biochemical-
based parameters and models.  Notable is the paucity
of local reports on hepatic fibrosis and steatosis
imaging. Radiology has the advantage of non-invasive
imaging of the liver and biliary tract and its related
vasculature in the context of fibrosis and the subsequent
complications. The spectrum includes gray scale and
Doppler ultrasound as the basic modality supple-
mented by transient elastography (TE), CT scanning,
MRI including MR Elastography (MRE), single positron
emission tomography (SPECT) and even dual energy
X-ray absorptiometry (DEXA) scanning.
Fibrosis is associated with scarring and increasing liver
stiffness so that the liver surface becomes rough and
finally irregular with blunting of the inferior edge. It was
initially believed that fibrosis cannot be detected or
evaluated with ultrasound.10 This view has been
questioned time and again with reports of accurate
grading with simultaneous use of multiple-frequency
probes and a combination of gray scale and Doppler
parameters which serve to improve the accuracy of
sonographic diagnosis and grading of fibrosis quite
comparable to histopathology.11,12 However, the concept
remains debatable with conflicting reports pouring in
and, therefore, research vistas remain open.
The same morphological change i.e. increasing liver
stiffness can also be evaluated with TE, MRE and
DEXA. TE introduced under the brand name of
'Fibroscan' caught on the fancy of clinicians in the belief
that it may provide a reliable alternative to biopsy for the
evaluation of fibrosis. It measures liver stiffness in units
termed kPa and the stiffness itself is displayed as a
spectrum of blue to green colour superimposed over the
gray scale ultrasound image. However, with increased
experience, its limitations have been recognized as an
inability to differentiate between the cause of stiffness
with steatosis, fibrosis and deposition disorders such as
amyloidosis giving nearly the same results and obesity
being a considerable technical limitation.13-15 In
Pakistan, very few centres have the equipment; the
clinical utility is under establishment and yet to gain the
clinician's confidence. Cost and limited experience
are very important considerations in its widespread
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acceptability and evidence-based reports are certainly
needed on this aspect from the centres that are actually
using the modality.
MRI uses many diffusion based chemical shift and
elastography techniques for evaluation of fibrosis. MRE
also measures hepatic stiffness measurements in kPa
with steatohepatitis without fibrosis having greater
stiffness (mean of 3.24 kPa) than simple steatosis
(mean kPa of 2.51) and lower than fibrosis (mean 4.16
kPa).16 MRE is reported to have an even greater ability
than DWI to distinguish between the stages of fibrosis.17
At present, the use of the various MR techniques is
limited by restricted availability of the equipment and the
high cost of the technique.
Perfusions changes on CT scanning and mean contrast
time perfusing through the liver is said to have the
potential of discriminating between the various stages of
fibrosis.18 The accuracy is yet to be proved with gold
standard.
To sum-up imaging hepatic fibrosis remains an under-
utilized and overlooked possibility in the current local
clinical settings. This might be due to the fact that the
cost-effective modality (ultrasound) has high operator
dependability making its results as subjective. While
the more objective techniques are either very costly or
unavailable; this limits their feasibility. Still, the trends in
fibrosis evaluation are undergoing a change and a shift
to imaging from biochemistry and histopathology needs
to be worked upon based on local evidence.
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